Streetbeat News

Analyst Ratings

EGAN

Craig-Hallum analyst Jeff Van Rhee maintains a Hold rating on eGain (NASDAQ:EGAN) and raises the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 1:06 pm

DOCU

Wells Fargo analyst Michael Turrin maintains an Underweight rating on DocuSign (NASDAQ:DOCU) but raises the price target from $48 to $50.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 1:05 pm

ZETA

Craig-Hallum analyst Jason Kreyer has maintained a Buy rating on Zeta Global Holdings and raised the price target from $32 to $35.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 1:05 pm

TVTX

B of A Securities analyst Greg Harrison maintains a Buy rating on Travere Therapeutics and raises the price target from $18 to $19.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 1:03 pm

MMI

Wells Fargo analyst Blaine Heck maintains an Underweight rating on Marcus & Millichap (NYSE:MMI) but raises the price target from $20 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 1:03 pm

RDNT

RadNet (NASDAQ:RDNT) has received mixed analyst ratings over the past three months, with a recent increase in average price targets from $56.00 to $66.4. Analysts have raised their ratings and price targets, indicating a positive outlook. Despite this, RadNet faces financial challenges, including a high debt-to-equity ratio and below-industry-average net margins, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 1:02 pm

VFC

In the past three months, 16 analysts have rated VF Corporation (NYSE:VFC), with most being indifferent. The average 12-month price target has increased by 22.28% to $15.75. Analysts have raised their price targets, reflecting a more positive outlook despite VF's revenue and profitability challenges.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 1:01 pm

TT

Wells Fargo analyst Joe O'Dea maintains an Underweight rating on Trane Technologies (NYSE:TT) but raises the price target from $315 to $320.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 1:01 pm

SEM

Select Medical Holdings (NYSE:SEM) has been analyzed by 5 analysts, all of whom are bullish. The average 12-month price target is $46.8, slightly up from $46.5. The company shows strong financial metrics but faces high debt levels.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 1:01 pm

COR

Cencora (NYSE:COR) has been analyzed by six analysts, showing a range of sentiments from somewhat bullish to indifferent. The average 12-month price target has increased by 1.4% to $277.67. Analysts have adjusted their ratings and price targets, reflecting their response to recent developments. Cencora is a leading pharmaceutical wholesaler with strong financial performance, including a 10.9% revenue growth rate and a high return on equity. However, it has a high debt-to-equity ratio, indicating financial risk.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 1:00 pm